Choose a Section
Most recent by Nirav N. Shah, MD
SPONSORED CONTENT
December 10, 2022
3 min read
Save
Ibrutinib could become new standard for first-line treatment of mantle cell lymphoma
NEW ORLEANS — Patients with newly diagnosed mantle cell lymphoma who received ibrutinib with a standard-of-care regimen had higher failure-free survival rates than those who received standard-of-care treatment alone.
SPONSORED CONTENT
December 11, 2021
3 min read
Save
EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL
Second-line therapy with axicabtagene ciloleucel conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma, according to results of a randomized phase 3 study.
SPONSORED CONTENT
July 23, 2019
4 min read
Save
CAR T-cell therapies may be cost-effective for patients with lymphoma subtype
The chimeric antigen receptor T-cell therapies axicabtagene ciloleucel and tisagenlecleucel may meet a cost-effectiveness threshold of less than $150,000 per quality-adjusted life-year gained for adults with diffuse large B-cell lymphoma, according to results of a study published in Journal of Clinical Oncology.